Arcutis Biotherapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Arcutis Biotherapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $376.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $196.54M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $59.61M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $3.69M | Feb 25, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.14M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($140.04M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($262.14M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($311.46M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($206.36M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($34.05M) | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | ($38.20M) | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | ($35.41M) | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | ($28.01M) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | ($12.57M) | Feb 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.23M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($128.40M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($241.10M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($301.63M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($206.53M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($136.65M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($43.13M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($19.74M) | Feb 16, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.05M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $76.42M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $110.58M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $182.44M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $145.56M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $115.31M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $36.52M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $17.94M | Feb 16, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $274.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $229.39M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $185.15M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $122.12M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $60.97M | Feb 27, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.63M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($112.16M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($247.06M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($257.72M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($174.63M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($113.03M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($42.84M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($14.09M) | Feb 16, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $686.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $143.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $428.0K | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $333.0K | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $995.0K | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $321.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $295.0K | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Feb 16, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $432.97M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $348.89M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $341.37M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $449.27M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $408.15M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $298.27M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $107.01M | Feb 16, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $243.49M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $191.35M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $252.70M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $239.69M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $110.48M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $27.65M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.55M | Feb 16, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.48M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $157.54M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $88.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $209.58M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $297.68M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $270.62M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | ($65.03M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($23.99M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | ($4.99M) | Feb 16, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.14B) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($1.12B) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($981.90M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($719.76M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($408.31M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($201.95M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | ($66.27M) | Feb 16, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.91M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $71.34M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $88.40M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $53.64M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $96.45M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $65.08M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $63.34M | Feb 16, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.96M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $107.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $201.80M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $197.77M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $72.35M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 22, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (5) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (22) | Feb 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (5) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (22) | Feb 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 123.33M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 117.85M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 96.79M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 61.04M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 50.26M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 43.34M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 2.12M | Feb 16, 2021 |